nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—malignant glioma	0.482	1	CbGaD
Lenalidomide—TNFSF11—skull—malignant glioma	0.0379	0.267	CbGeAlD
Lenalidomide—CDH5—endothelium—malignant glioma	0.0128	0.09	CbGeAlD
Lenalidomide—CDH5—blood vessel—malignant glioma	0.0118	0.083	CbGeAlD
Lenalidomide—TNFSF11—embryo—malignant glioma	0.00935	0.0658	CbGeAlD
Lenalidomide—CDH5—embryo—malignant glioma	0.00703	0.0495	CbGeAlD
Lenalidomide—CDH5—medulla oblongata—malignant glioma	0.00449	0.0316	CbGeAlD
Lenalidomide—CRBN—embryo—malignant glioma	0.00447	0.0315	CbGeAlD
Lenalidomide—CDH5—midbrain—malignant glioma	0.00411	0.0289	CbGeAlD
Lenalidomide—CDH5—spinal cord—malignant glioma	0.00401	0.0282	CbGeAlD
Lenalidomide—CRBN—retina—malignant glioma	0.00395	0.0278	CbGeAlD
Lenalidomide—CRBN—telencephalon—malignant glioma	0.00363	0.0256	CbGeAlD
Lenalidomide—CDH5—central nervous system—malignant glioma	0.00325	0.0229	CbGeAlD
Lenalidomide—CDH5—cerebellum—malignant glioma	0.00318	0.0224	CbGeAlD
Lenalidomide—Pomalidomide—TNF—malignant glioma	0.00299	0.338	CrCbGaD
Lenalidomide—CRBN—medulla oblongata—malignant glioma	0.00285	0.0201	CbGeAlD
Lenalidomide—CRBN—midbrain—malignant glioma	0.00261	0.0184	CbGeAlD
Lenalidomide—CDH5—brain—malignant glioma	0.00258	0.0182	CbGeAlD
Lenalidomide—CRBN—spinal cord—malignant glioma	0.00255	0.0179	CbGeAlD
Lenalidomide—PTGS2—endothelium—malignant glioma	0.00221	0.0156	CbGeAlD
Lenalidomide—Interstitial pneumonia—Temozolomide—malignant glioma	0.0022	0.01	CcSEcCtD
Lenalidomide—Cerebral ischaemia—Temozolomide—malignant glioma	0.0022	0.01	CcSEcCtD
Lenalidomide—Transient ischaemic attack—Temozolomide—malignant glioma	0.0021	0.00958	CcSEcCtD
Lenalidomide—Lymphopenia—Temozolomide—malignant glioma	0.00208	0.00945	CcSEcCtD
Lenalidomide—CRBN—central nervous system—malignant glioma	0.00206	0.0145	CbGeAlD
Lenalidomide—Azotaemia—Carmustine—malignant glioma	0.00206	0.00939	CcSEcCtD
Lenalidomide—PTGS2—blood vessel—malignant glioma	0.00204	0.0144	CbGeAlD
Lenalidomide—CRBN—cerebellum—malignant glioma	0.00202	0.0142	CbGeAlD
Lenalidomide—Thalidomide—TNF—malignant glioma	0.00192	0.218	CrCbGaD
Lenalidomide—Skin hyperpigmentation—Carmustine—malignant glioma	0.00185	0.00841	CcSEcCtD
Lenalidomide—Febrile neutropenia—Carmustine—malignant glioma	0.00183	0.00832	CcSEcCtD
Lenalidomide—Haemorrhoids—Temozolomide—malignant glioma	0.00181	0.00822	CcSEcCtD
Lenalidomide—Visual acuity reduced—Temozolomide—malignant glioma	0.00179	0.00813	CcSEcCtD
Lenalidomide—Febrile neutropenia—Temozolomide—malignant glioma	0.00177	0.00804	CcSEcCtD
Lenalidomide—Deep vein thrombosis—Temozolomide—malignant glioma	0.00175	0.00795	CcSEcCtD
Lenalidomide—Oral candidiasis—Carmustine—malignant glioma	0.00173	0.00788	CcSEcCtD
Lenalidomide—Aphasia—Carmustine—malignant glioma	0.00169	0.00771	CcSEcCtD
Lenalidomide—Oral candidiasis—Temozolomide—malignant glioma	0.00167	0.00761	CcSEcCtD
Lenalidomide—Embolism—Temozolomide—malignant glioma	0.00165	0.00753	CcSEcCtD
Lenalidomide—Cyst—Carmustine—malignant glioma	0.00164	0.00748	CcSEcCtD
Lenalidomide—CRBN—brain—malignant glioma	0.00164	0.0115	CbGeAlD
Lenalidomide—Aphasia—Temozolomide—malignant glioma	0.00164	0.00745	CcSEcCtD
Lenalidomide—Thalidomide—PTGS1—malignant glioma	0.0016	0.181	CrCbGaD
Lenalidomide—Burning sensation—Carmustine—malignant glioma	0.00158	0.0072	CcSEcCtD
Lenalidomide—Thrombosis—Carmustine—malignant glioma	0.00155	0.00707	CcSEcCtD
Lenalidomide—Interstitial lung disease—Carmustine—malignant glioma	0.00155	0.00707	CcSEcCtD
Lenalidomide—Interstitial lung disease—Temozolomide—malignant glioma	0.0015	0.00683	CcSEcCtD
Lenalidomide—Hepatotoxicity—Carmustine—malignant glioma	0.00142	0.00648	CcSEcCtD
Lenalidomide—Pomalidomide—PTGS2—malignant glioma	0.00142	0.16	CrCbGaD
Lenalidomide—Cholestasis—Temozolomide—malignant glioma	0.0014	0.00637	CcSEcCtD
Lenalidomide—Abscess—Carmustine—malignant glioma	0.00139	0.00632	CcSEcCtD
Lenalidomide—Hepatotoxicity—Temozolomide—malignant glioma	0.00138	0.00626	CcSEcCtD
Lenalidomide—Coagulopathy—Temozolomide—malignant glioma	0.00136	0.00621	CcSEcCtD
Lenalidomide—Rigors—Temozolomide—malignant glioma	0.0013	0.00592	CcSEcCtD
Lenalidomide—Petechiae—Temozolomide—malignant glioma	0.00129	0.00588	CcSEcCtD
Lenalidomide—Endocrine disorder—Temozolomide—malignant glioma	0.00128	0.00583	CcSEcCtD
Lenalidomide—Speech disorder—Carmustine—malignant glioma	0.00128	0.00582	CcSEcCtD
Lenalidomide—ABCB1—blood vessel—malignant glioma	0.00126	0.00888	CbGeAlD
Lenalidomide—Speech disorder—Temozolomide—malignant glioma	0.00123	0.00562	CcSEcCtD
Lenalidomide—PTGS2—embryo—malignant glioma	0.00122	0.00856	CbGeAlD
Lenalidomide—Amenorrhoea—Temozolomide—malignant glioma	0.00121	0.0055	CcSEcCtD
Lenalidomide—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.00117	0.00532	CcSEcCtD
Lenalidomide—Herpes simplex—Temozolomide—malignant glioma	0.00115	0.00525	CcSEcCtD
Lenalidomide—Gait disturbance—Carmustine—malignant glioma	0.00113	0.00513	CcSEcCtD
Lenalidomide—Hearing impaired—Temozolomide—malignant glioma	0.00112	0.00508	CcSEcCtD
Lenalidomide—Neck pain—Carmustine—malignant glioma	0.00111	0.00506	CcSEcCtD
Lenalidomide—Pulmonary embolism—Carmustine—malignant glioma	0.0011	0.005	CcSEcCtD
Lenalidomide—Gait disturbance—Temozolomide—malignant glioma	0.00109	0.00495	CcSEcCtD
Lenalidomide—Respiratory failure—Temozolomide—malignant glioma	0.00108	0.00492	CcSEcCtD
Lenalidomide—Musculoskeletal pain—Temozolomide—malignant glioma	0.00107	0.00489	CcSEcCtD
Lenalidomide—Pulmonary embolism—Temozolomide—malignant glioma	0.00106	0.00484	CcSEcCtD
Lenalidomide—Urinary incontinence—Carmustine—malignant glioma	0.00106	0.00483	CcSEcCtD
Lenalidomide—Depressed level of consciousness—Carmustine—malignant glioma	0.00106	0.00483	CcSEcCtD
Lenalidomide—Candida infection—Carmustine—malignant glioma	0.00105	0.00478	CcSEcCtD
Lenalidomide—Neuropathy—Carmustine—malignant glioma	0.00103	0.0047	CcSEcCtD
Lenalidomide—Influenza like illness—Temozolomide—malignant glioma	0.00103	0.0047	CcSEcCtD
Lenalidomide—Urinary incontinence—Temozolomide—malignant glioma	0.00103	0.00467	CcSEcCtD
Lenalidomide—Depressed level of consciousness—Temozolomide—malignant glioma	0.00103	0.00467	CcSEcCtD
Lenalidomide—Candida infection—Temozolomide—malignant glioma	0.00101	0.00462	CcSEcCtD
Lenalidomide—Neuropathy—Temozolomide—malignant glioma	0.000997	0.00454	CcSEcCtD
Lenalidomide—Neoplasm—Carmustine—malignant glioma	0.000993	0.00452	CcSEcCtD
Lenalidomide—PTGS2—telencephalon—malignant glioma	0.000989	0.00697	CbGeAlD
Lenalidomide—Gynaecomastia—Carmustine—malignant glioma	0.000983	0.00448	CcSEcCtD
Lenalidomide—Dry eye—Temozolomide—malignant glioma	0.000981	0.00447	CcSEcCtD
Lenalidomide—Neoplasm—Temozolomide—malignant glioma	0.00096	0.00437	CcSEcCtD
Lenalidomide—Sepsis—Carmustine—malignant glioma	0.000954	0.00434	CcSEcCtD
Lenalidomide—Thrombophlebitis—Carmustine—malignant glioma	0.000921	0.0042	CcSEcCtD
Lenalidomide—Diabetes mellitus—Carmustine—malignant glioma	0.000917	0.00418	CcSEcCtD
Lenalidomide—Thalidomide—PTGS2—malignant glioma	0.000914	0.103	CrCbGaD
Lenalidomide—Ear pain—Temozolomide—malignant glioma	0.000903	0.00411	CcSEcCtD
Lenalidomide—Thrombophlebitis—Temozolomide—malignant glioma	0.00089	0.00405	CcSEcCtD
Lenalidomide—Gastroenteritis—Temozolomide—malignant glioma	0.00087	0.00396	CcSEcCtD
Lenalidomide—Deafness—Temozolomide—malignant glioma	0.000862	0.00392	CcSEcCtD
Lenalidomide—Hepatic failure—Temozolomide—malignant glioma	0.000858	0.00391	CcSEcCtD
Lenalidomide—Nasal congestion—Temozolomide—malignant glioma	0.000846	0.00385	CcSEcCtD
Lenalidomide—Hyponatraemia—Carmustine—malignant glioma	0.000801	0.00365	CcSEcCtD
Lenalidomide—Diplopia—Carmustine—malignant glioma	0.000798	0.00363	CcSEcCtD
Lenalidomide—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000798	0.00363	CcSEcCtD
Lenalidomide—PTGS2—medulla oblongata—malignant glioma	0.000777	0.00547	CbGeAlD
Lenalidomide—Diplopia—Temozolomide—malignant glioma	0.000771	0.00351	CcSEcCtD
Lenalidomide—Face oedema—Carmustine—malignant glioma	0.00077	0.00351	CcSEcCtD
Lenalidomide—Affect lability—Temozolomide—malignant glioma	0.000759	0.00345	CcSEcCtD
Lenalidomide—ABCB1—embryo—malignant glioma	0.000752	0.0053	CbGeAlD
Lenalidomide—Ataxia—Carmustine—malignant glioma	0.00075	0.00341	CcSEcCtD
Lenalidomide—Face oedema—Temozolomide—malignant glioma	0.000744	0.00339	CcSEcCtD
Lenalidomide—Liver function test abnormal—Carmustine—malignant glioma	0.000736	0.00335	CcSEcCtD
Lenalidomide—Mood swings—Temozolomide—malignant glioma	0.00073	0.00332	CcSEcCtD
Lenalidomide—Hypokalaemia—Carmustine—malignant glioma	0.000726	0.00331	CcSEcCtD
Lenalidomide—Ataxia—Temozolomide—malignant glioma	0.000725	0.0033	CcSEcCtD
Lenalidomide—Dehydration—Temozolomide—malignant glioma	0.000717	0.00326	CcSEcCtD
Lenalidomide—PTGS2—midbrain—malignant glioma	0.00071	0.005	CbGeAlD
Lenalidomide—Dry skin—Temozolomide—malignant glioma	0.000707	0.00322	CcSEcCtD
Lenalidomide—Muscular weakness—Carmustine—malignant glioma	0.000704	0.0032	CcSEcCtD
Lenalidomide—Hypokalaemia—Temozolomide—malignant glioma	0.000702	0.00319	CcSEcCtD
Lenalidomide—Breast disorder—Temozolomide—malignant glioma	0.000697	0.00317	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000694	0.00316	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000694	0.00316	CcSEcCtD
Lenalidomide—PTGS2—spinal cord—malignant glioma	0.000693	0.00488	CbGeAlD
Lenalidomide—Dysphagia—Carmustine—malignant glioma	0.000689	0.00314	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00068	0.0031	CcSEcCtD
Lenalidomide—Muscular weakness—Temozolomide—malignant glioma	0.00068	0.0031	CcSEcCtD
Lenalidomide—Abdominal distension—Temozolomide—malignant glioma	0.000671	0.00305	CcSEcCtD
Lenalidomide—Dysphagia—Temozolomide—malignant glioma	0.000666	0.00303	CcSEcCtD
Lenalidomide—ABCB1—retina—malignant glioma	0.000665	0.00468	CbGeAlD
Lenalidomide—Pancytopenia—Carmustine—malignant glioma	0.000655	0.00298	CcSEcCtD
Lenalidomide—Sweating increased—Temozolomide—malignant glioma	0.000649	0.00295	CcSEcCtD
Lenalidomide—Neutropenia—Carmustine—malignant glioma	0.000645	0.00294	CcSEcCtD
Lenalidomide—Bronchitis—Temozolomide—malignant glioma	0.000641	0.00292	CcSEcCtD
Lenalidomide—Pancytopenia—Temozolomide—malignant glioma	0.000633	0.00288	CcSEcCtD
Lenalidomide—Dysuria—Temozolomide—malignant glioma	0.000623	0.00284	CcSEcCtD
Lenalidomide—Neutropenia—Temozolomide—malignant glioma	0.000623	0.00284	CcSEcCtD
Lenalidomide—Hyperglycaemia—Carmustine—malignant glioma	0.000622	0.00283	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000619	0.00282	CcSEcCtD
Lenalidomide—Pneumonia—Carmustine—malignant glioma	0.000618	0.00282	CcSEcCtD
Lenalidomide—Pollakiuria—Temozolomide—malignant glioma	0.000615	0.0028	CcSEcCtD
Lenalidomide—Erectile dysfunction—Temozolomide—malignant glioma	0.000614	0.00279	CcSEcCtD
Lenalidomide—Depression—Carmustine—malignant glioma	0.000613	0.00279	CcSEcCtD
Lenalidomide—ABCB1—telencephalon—malignant glioma	0.000612	0.00431	CbGeAlD
Lenalidomide—Photosensitivity reaction—Temozolomide—malignant glioma	0.000608	0.00277	CcSEcCtD
Lenalidomide—Weight increased—Temozolomide—malignant glioma	0.000606	0.00276	CcSEcCtD
Lenalidomide—Renal failure—Carmustine—malignant glioma	0.000604	0.00275	CcSEcCtD
Lenalidomide—Weight decreased—Temozolomide—malignant glioma	0.000603	0.00274	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Carmustine—malignant glioma	0.000603	0.00274	CcSEcCtD
Lenalidomide—Hyperglycaemia—Temozolomide—malignant glioma	0.000601	0.00274	CcSEcCtD
Lenalidomide—Stomatitis—Carmustine—malignant glioma	0.000599	0.00273	CcSEcCtD
Lenalidomide—Urinary tract infection—Carmustine—malignant glioma	0.000597	0.00272	CcSEcCtD
Lenalidomide—Pneumonia—Temozolomide—malignant glioma	0.000597	0.00272	CcSEcCtD
Lenalidomide—Infestation—Temozolomide—malignant glioma	0.000594	0.0027	CcSEcCtD
Lenalidomide—Infestation NOS—Temozolomide—malignant glioma	0.000594	0.0027	CcSEcCtD
Lenalidomide—Depression—Temozolomide—malignant glioma	0.000592	0.0027	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000589	0.00268	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Temozolomide—malignant glioma	0.000582	0.00265	CcSEcCtD
Lenalidomide—Stomatitis—Temozolomide—malignant glioma	0.000579	0.00264	CcSEcCtD
Lenalidomide—Urinary tract infection—Temozolomide—malignant glioma	0.000577	0.00263	CcSEcCtD
Lenalidomide—PTGS2—central nervous system—malignant glioma	0.000562	0.00396	CbGeAlD
Lenalidomide—Hepatobiliary disease—Temozolomide—malignant glioma	0.000562	0.00256	CcSEcCtD
Lenalidomide—Sinusitis—Temozolomide—malignant glioma	0.000557	0.00254	CcSEcCtD
Lenalidomide—Haemoglobin—Carmustine—malignant glioma	0.000555	0.00253	CcSEcCtD
Lenalidomide—Haemorrhage—Carmustine—malignant glioma	0.000552	0.00251	CcSEcCtD
Lenalidomide—PTGS2—cerebellum—malignant glioma	0.00055	0.00387	CbGeAlD
Lenalidomide—Hallucination—Carmustine—malignant glioma	0.000549	0.0025	CcSEcCtD
Lenalidomide—Hypoaesthesia—Carmustine—malignant glioma	0.000549	0.0025	CcSEcCtD
Lenalidomide—Oedema peripheral—Carmustine—malignant glioma	0.000544	0.00248	CcSEcCtD
Lenalidomide—Connective tissue disorder—Carmustine—malignant glioma	0.000542	0.00247	CcSEcCtD
Lenalidomide—Haemoglobin—Temozolomide—malignant glioma	0.000536	0.00244	CcSEcCtD
Lenalidomide—Haemorrhage—Temozolomide—malignant glioma	0.000533	0.00243	CcSEcCtD
Lenalidomide—Hepatitis—Temozolomide—malignant glioma	0.000533	0.00243	CcSEcCtD
Lenalidomide—Visual impairment—Carmustine—malignant glioma	0.000532	0.00242	CcSEcCtD
Lenalidomide—Hallucination—Temozolomide—malignant glioma	0.000531	0.00242	CcSEcCtD
Lenalidomide—Hypoaesthesia—Temozolomide—malignant glioma	0.000531	0.00242	CcSEcCtD
Lenalidomide—Pharyngitis—Temozolomide—malignant glioma	0.000529	0.00241	CcSEcCtD
Lenalidomide—Urinary tract disorder—Temozolomide—malignant glioma	0.000527	0.0024	CcSEcCtD
Lenalidomide—Oedema peripheral—Temozolomide—malignant glioma	0.000525	0.00239	CcSEcCtD
Lenalidomide—Connective tissue disorder—Temozolomide—malignant glioma	0.000524	0.00239	CcSEcCtD
Lenalidomide—Urethral disorder—Temozolomide—malignant glioma	0.000523	0.00238	CcSEcCtD
Lenalidomide—Eye disorder—Carmustine—malignant glioma	0.000516	0.00235	CcSEcCtD
Lenalidomide—Visual impairment—Temozolomide—malignant glioma	0.000514	0.00234	CcSEcCtD
Lenalidomide—Flushing—Carmustine—malignant glioma	0.000512	0.00233	CcSEcCtD
Lenalidomide—Erythema multiforme—Temozolomide—malignant glioma	0.000504	0.0023	CcSEcCtD
Lenalidomide—Eye disorder—Temozolomide—malignant glioma	0.000498	0.00227	CcSEcCtD
Lenalidomide—Tinnitus—Temozolomide—malignant glioma	0.000497	0.00226	CcSEcCtD
Lenalidomide—Cardiac disorder—Temozolomide—malignant glioma	0.000495	0.00225	CcSEcCtD
Lenalidomide—Flushing—Temozolomide—malignant glioma	0.000495	0.00225	CcSEcCtD
Lenalidomide—Arrhythmia—Carmustine—malignant glioma	0.000493	0.00224	CcSEcCtD
Lenalidomide—Alopecia—Carmustine—malignant glioma	0.000488	0.00222	CcSEcCtD
Lenalidomide—Angiopathy—Temozolomide—malignant glioma	0.000484	0.0022	CcSEcCtD
Lenalidomide—Mental disorder—Carmustine—malignant glioma	0.000483	0.0022	CcSEcCtD
Lenalidomide—Immune system disorder—Temozolomide—malignant glioma	0.000482	0.00219	CcSEcCtD
Lenalidomide—ABCB1—medulla oblongata—malignant glioma	0.000481	0.00339	CbGeAlD
Lenalidomide—Mediastinal disorder—Temozolomide—malignant glioma	0.000481	0.00219	CcSEcCtD
Lenalidomide—Malnutrition—Carmustine—malignant glioma	0.00048	0.00219	CcSEcCtD
Lenalidomide—Erythema—Carmustine—malignant glioma	0.00048	0.00219	CcSEcCtD
Lenalidomide—Chills—Temozolomide—malignant glioma	0.000478	0.00218	CcSEcCtD
Lenalidomide—Alopecia—Temozolomide—malignant glioma	0.000471	0.00215	CcSEcCtD
Lenalidomide—Mental disorder—Temozolomide—malignant glioma	0.000467	0.00213	CcSEcCtD
Lenalidomide—Back pain—Carmustine—malignant glioma	0.000465	0.00212	CcSEcCtD
Lenalidomide—Erythema—Temozolomide—malignant glioma	0.000464	0.00211	CcSEcCtD
Lenalidomide—Malnutrition—Temozolomide—malignant glioma	0.000464	0.00211	CcSEcCtD
Lenalidomide—Dysgeusia—Temozolomide—malignant glioma	0.000455	0.00207	CcSEcCtD
Lenalidomide—Vision blurred—Carmustine—malignant glioma	0.000453	0.00206	CcSEcCtD
Lenalidomide—Tremor—Carmustine—malignant glioma	0.00045	0.00205	CcSEcCtD
Lenalidomide—Back pain—Temozolomide—malignant glioma	0.000449	0.00204	CcSEcCtD
Lenalidomide—PTGS2—brain—malignant glioma	0.000446	0.00314	CbGeAlD
Lenalidomide—Anaemia—Carmustine—malignant glioma	0.000444	0.00202	CcSEcCtD
Lenalidomide—Agitation—Carmustine—malignant glioma	0.000441	0.00201	CcSEcCtD
Lenalidomide—ABCB1—midbrain—malignant glioma	0.000439	0.00309	CbGeAlD
Lenalidomide—Vision blurred—Temozolomide—malignant glioma	0.000437	0.00199	CcSEcCtD
Lenalidomide—Tremor—Temozolomide—malignant glioma	0.000435	0.00198	CcSEcCtD
Lenalidomide—Ill-defined disorder—Temozolomide—malignant glioma	0.000431	0.00196	CcSEcCtD
Lenalidomide—Leukopenia—Carmustine—malignant glioma	0.00043	0.00196	CcSEcCtD
Lenalidomide—Anaemia—Temozolomide—malignant glioma	0.000429	0.00195	CcSEcCtD
Lenalidomide—ABCB1—spinal cord—malignant glioma	0.000429	0.00302	CbGeAlD
Lenalidomide—Agitation—Temozolomide—malignant glioma	0.000427	0.00194	CcSEcCtD
Lenalidomide—Angioedema—Temozolomide—malignant glioma	0.000424	0.00193	CcSEcCtD
Lenalidomide—Malaise—Temozolomide—malignant glioma	0.000419	0.00191	CcSEcCtD
Lenalidomide—Vertigo—Temozolomide—malignant glioma	0.000417	0.0019	CcSEcCtD
Lenalidomide—Leukopenia—Temozolomide—malignant glioma	0.000416	0.00189	CcSEcCtD
Lenalidomide—Hypertension—Carmustine—malignant glioma	0.000415	0.00189	CcSEcCtD
Lenalidomide—Palpitations—Temozolomide—malignant glioma	0.00041	0.00187	CcSEcCtD
Lenalidomide—Myalgia—Carmustine—malignant glioma	0.000409	0.00186	CcSEcCtD
Lenalidomide—Chest pain—Carmustine—malignant glioma	0.000409	0.00186	CcSEcCtD
Lenalidomide—Anxiety—Carmustine—malignant glioma	0.000408	0.00186	CcSEcCtD
Lenalidomide—Cough—Temozolomide—malignant glioma	0.000405	0.00184	CcSEcCtD
Lenalidomide—Hypertension—Temozolomide—malignant glioma	0.000401	0.00182	CcSEcCtD
Lenalidomide—Confusional state—Carmustine—malignant glioma	0.000395	0.0018	CcSEcCtD
Lenalidomide—Myalgia—Temozolomide—malignant glioma	0.000395	0.0018	CcSEcCtD
Lenalidomide—Arthralgia—Temozolomide—malignant glioma	0.000395	0.0018	CcSEcCtD
Lenalidomide—Anxiety—Temozolomide—malignant glioma	0.000394	0.00179	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000392	0.00179	CcSEcCtD
Lenalidomide—Oedema—Carmustine—malignant glioma	0.000392	0.00178	CcSEcCtD
Lenalidomide—Discomfort—Temozolomide—malignant glioma	0.00039	0.00178	CcSEcCtD
Lenalidomide—Infection—Carmustine—malignant glioma	0.000389	0.00177	CcSEcCtD
Lenalidomide—Dry mouth—Temozolomide—malignant glioma	0.000387	0.00176	CcSEcCtD
Lenalidomide—Thrombocytopenia—Carmustine—malignant glioma	0.000384	0.00175	CcSEcCtD
Lenalidomide—Tachycardia—Carmustine—malignant glioma	0.000383	0.00174	CcSEcCtD
Lenalidomide—Confusional state—Temozolomide—malignant glioma	0.000382	0.00174	CcSEcCtD
Lenalidomide—Oedema—Temozolomide—malignant glioma	0.000379	0.00172	CcSEcCtD
Lenalidomide—Infection—Temozolomide—malignant glioma	0.000376	0.00171	CcSEcCtD
Lenalidomide—Anorexia—Carmustine—malignant glioma	0.000374	0.0017	CcSEcCtD
Lenalidomide—Nervous system disorder—Temozolomide—malignant glioma	0.000372	0.00169	CcSEcCtD
Lenalidomide—Thrombocytopenia—Temozolomide—malignant glioma	0.000371	0.00169	CcSEcCtD
Lenalidomide—Skin disorder—Temozolomide—malignant glioma	0.000368	0.00168	CcSEcCtD
Lenalidomide—Hypotension—Carmustine—malignant glioma	0.000366	0.00167	CcSEcCtD
Lenalidomide—Hyperhidrosis—Temozolomide—malignant glioma	0.000366	0.00167	CcSEcCtD
Lenalidomide—Anorexia—Temozolomide—malignant glioma	0.000361	0.00164	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000357	0.00163	CcSEcCtD
Lenalidomide—Insomnia—Carmustine—malignant glioma	0.000355	0.00161	CcSEcCtD
Lenalidomide—Paraesthesia—Carmustine—malignant glioma	0.000352	0.0016	CcSEcCtD
Lenalidomide—Dyspnoea—Carmustine—malignant glioma	0.00035	0.00159	CcSEcCtD
Lenalidomide—Somnolence—Carmustine—malignant glioma	0.000349	0.00159	CcSEcCtD
Lenalidomide—ABCB1—central nervous system—malignant glioma	0.000348	0.00245	CbGeAlD
Lenalidomide—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000345	0.00157	CcSEcCtD
Lenalidomide—Insomnia—Temozolomide—malignant glioma	0.000343	0.00156	CcSEcCtD
Lenalidomide—Decreased appetite—Carmustine—malignant glioma	0.000341	0.00155	CcSEcCtD
Lenalidomide—Paraesthesia—Temozolomide—malignant glioma	0.00034	0.00155	CcSEcCtD
Lenalidomide—ABCB1—cerebellum—malignant glioma	0.00034	0.00239	CbGeAlD
Lenalidomide—Gastrointestinal disorder—Carmustine—malignant glioma	0.000338	0.00154	CcSEcCtD
Lenalidomide—Dyspnoea—Temozolomide—malignant glioma	0.000338	0.00154	CcSEcCtD
Lenalidomide—Somnolence—Temozolomide—malignant glioma	0.000337	0.00153	CcSEcCtD
Lenalidomide—Pain—Carmustine—malignant glioma	0.000335	0.00153	CcSEcCtD
Lenalidomide—Constipation—Carmustine—malignant glioma	0.000335	0.00153	CcSEcCtD
Lenalidomide—Dyspepsia—Temozolomide—malignant glioma	0.000333	0.00152	CcSEcCtD
Lenalidomide—Decreased appetite—Temozolomide—malignant glioma	0.000329	0.0015	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000327	0.00149	CcSEcCtD
Lenalidomide—Fatigue—Temozolomide—malignant glioma	0.000327	0.00149	CcSEcCtD
Lenalidomide—Pain—Temozolomide—malignant glioma	0.000324	0.00148	CcSEcCtD
Lenalidomide—Constipation—Temozolomide—malignant glioma	0.000324	0.00148	CcSEcCtD
Lenalidomide—Feeling abnormal—Carmustine—malignant glioma	0.000323	0.00147	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Carmustine—malignant glioma	0.000321	0.00146	CcSEcCtD
Lenalidomide—Feeling abnormal—Temozolomide—malignant glioma	0.000312	0.00142	CcSEcCtD
Lenalidomide—Body temperature increased—Carmustine—malignant glioma	0.00031	0.00141	CcSEcCtD
Lenalidomide—Abdominal pain—Carmustine—malignant glioma	0.00031	0.00141	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Temozolomide—malignant glioma	0.00031	0.00141	CcSEcCtD
Lenalidomide—Urticaria—Temozolomide—malignant glioma	0.000301	0.00137	CcSEcCtD
Lenalidomide—Abdominal pain—Temozolomide—malignant glioma	0.000299	0.00136	CcSEcCtD
Lenalidomide—Body temperature increased—Temozolomide—malignant glioma	0.000299	0.00136	CcSEcCtD
Lenalidomide—Hypersensitivity—Carmustine—malignant glioma	0.000289	0.00132	CcSEcCtD
Lenalidomide—Asthenia—Carmustine—malignant glioma	0.000281	0.00128	CcSEcCtD
Lenalidomide—Hypersensitivity—Temozolomide—malignant glioma	0.000279	0.00127	CcSEcCtD
Lenalidomide—ABCB1—brain—malignant glioma	0.000276	0.00194	CbGeAlD
Lenalidomide—Asthenia—Temozolomide—malignant glioma	0.000272	0.00124	CcSEcCtD
Lenalidomide—Diarrhoea—Carmustine—malignant glioma	0.000268	0.00122	CcSEcCtD
Lenalidomide—Pruritus—Temozolomide—malignant glioma	0.000268	0.00122	CcSEcCtD
Lenalidomide—Dizziness—Carmustine—malignant glioma	0.000259	0.00118	CcSEcCtD
Lenalidomide—Diarrhoea—Temozolomide—malignant glioma	0.000259	0.00118	CcSEcCtD
Lenalidomide—Dizziness—Temozolomide—malignant glioma	0.000251	0.00114	CcSEcCtD
Lenalidomide—Vomiting—Carmustine—malignant glioma	0.000249	0.00113	CcSEcCtD
Lenalidomide—Rash—Carmustine—malignant glioma	0.000247	0.00113	CcSEcCtD
Lenalidomide—Dermatitis—Carmustine—malignant glioma	0.000247	0.00112	CcSEcCtD
Lenalidomide—Headache—Carmustine—malignant glioma	0.000246	0.00112	CcSEcCtD
Lenalidomide—Vomiting—Temozolomide—malignant glioma	0.000241	0.0011	CcSEcCtD
Lenalidomide—Rash—Temozolomide—malignant glioma	0.000239	0.00109	CcSEcCtD
Lenalidomide—Dermatitis—Temozolomide—malignant glioma	0.000239	0.00109	CcSEcCtD
Lenalidomide—Headache—Temozolomide—malignant glioma	0.000237	0.00108	CcSEcCtD
Lenalidomide—Nausea—Carmustine—malignant glioma	0.000233	0.00106	CcSEcCtD
Lenalidomide—Nausea—Temozolomide—malignant glioma	0.000225	0.00102	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—BDKRB2—malignant glioma	0.000161	0.00109	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TOP2A—malignant glioma	0.000155	0.00105	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—malignant glioma	0.000154	0.00105	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—F2—malignant glioma	0.000152	0.00103	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH2—malignant glioma	0.000149	0.00101	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HIF1A—malignant glioma	0.000148	0.001	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—malignant glioma	0.000146	0.000992	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KNG1—malignant glioma	0.000146	0.000989	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—PDGFRA—malignant glioma	0.000145	0.000984	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-B—malignant glioma	0.000144	0.000977	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PLK1—malignant glioma	0.000142	0.000965	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NTRK1—malignant glioma	0.000139	0.000943	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—malignant glioma	0.000138	0.000933	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—malignant glioma	0.000135	0.000915	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—malignant glioma	0.000135	0.000912	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-A—malignant glioma	0.000134	0.000905	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—malignant glioma	0.000132	0.000893	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP3—malignant glioma	0.000129	0.000877	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN2B—malignant glioma	0.000128	0.000869	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RTEL1—malignant glioma	0.000126	0.000856	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—malignant glioma	0.000125	0.00085	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTK2—malignant glioma	0.000125	0.000844	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—malignant glioma	0.000124	0.000843	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—malignant glioma	0.000123	0.000832	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HES1—malignant glioma	0.000122	0.000829	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NCOR1—malignant glioma	0.000122	0.000824	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—BCL2—malignant glioma	0.000121	0.000819	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	0.000121	0.000818	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PML—malignant glioma	0.00012	0.000815	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—malignant glioma	0.000117	0.000795	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PDGFRA—malignant glioma	0.000117	0.000789	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IFNG—malignant glioma	0.000115	0.000782	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SPP1—malignant glioma	0.000113	0.000766	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD80—malignant glioma	0.000113	0.000764	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	0.000112	0.000761	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	0.000111	0.000754	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TOP2A—malignant glioma	0.00011	0.000746	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—COX8A—malignant glioma	0.00011	0.000744	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TERT—malignant glioma	0.000107	0.000726	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PDGFB—malignant glioma	0.000105	0.000709	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGFR1—malignant glioma	0.000104	0.000705	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL1B—malignant glioma	0.000103	0.000697	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HIF1A—malignant glioma	0.000103	0.000695	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	0.000101	0.000685	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—FTH1—malignant glioma	0.0001	0.00068	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CAV1—malignant glioma	9.92e-05	0.000672	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KDR—malignant glioma	9.81e-05	0.000664	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FN1—malignant glioma	9.44e-05	0.00064	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—F2—malignant glioma	9.44e-05	0.00064	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—BAD—malignant glioma	9.33e-05	0.000632	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH1—malignant glioma	9.24e-05	0.000626	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IFNG—malignant glioma	9.12e-05	0.000618	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—malignant glioma	9.08e-05	0.000615	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CD80—malignant glioma	9.05e-05	0.000613	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CG—malignant glioma	9.04e-05	0.000612	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APC—malignant glioma	9.04e-05	0.000612	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	9.03e-05	0.000612	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	9.03e-05	0.000611	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RTEL1—malignant glioma	8.95e-05	0.000606	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGF—malignant glioma	8.93e-05	0.000605	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IFNG—malignant glioma	8.92e-05	0.000604	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTPN11—malignant glioma	8.88e-05	0.000601	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ATP1B2—malignant glioma	8.78e-05	0.000595	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	8.73e-05	0.000592	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	8.56e-05	0.00058	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—APOD—malignant glioma	8.54e-05	0.000578	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—BRAF—malignant glioma	8.49e-05	0.000575	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—malignant glioma	8.48e-05	0.000575	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—malignant glioma	8.32e-05	0.000564	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—malignant glioma	8.29e-05	0.000562	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT2—malignant glioma	8.27e-05	0.00056	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1B—malignant glioma	8.14e-05	0.000551	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—malignant glioma	8.12e-05	0.00055	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—malignant glioma	8.11e-05	0.000549	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	8.09e-05	0.000548	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	7.96e-05	0.000539	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL1B—malignant glioma	7.95e-05	0.000539	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CD—malignant glioma	7.94e-05	0.000538	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—malignant glioma	7.94e-05	0.000538	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2—malignant glioma	7.92e-05	0.000537	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	7.89e-05	0.000534	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	7.84e-05	0.000531	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—malignant glioma	7.78e-05	0.000527	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	7.75e-05	0.000525	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—malignant glioma	7.69e-05	0.000521	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—malignant glioma	7.67e-05	0.00052	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF2—malignant glioma	7.61e-05	0.000515	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—malignant glioma	7.47e-05	0.000506	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—COX8A—malignant glioma	7.25e-05	0.000491	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	7.17e-05	0.000485	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MDM2—malignant glioma	7.12e-05	0.000482	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RAF1—malignant glioma	7.09e-05	0.00048	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—malignant glioma	7.02e-05	0.000475	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BCAN—malignant glioma	6.92e-05	0.000469	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CB—malignant glioma	6.92e-05	0.000469	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—malignant glioma	6.73e-05	0.000456	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—malignant glioma	6.65e-05	0.000451	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	6.6e-05	0.000447	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	6.48e-05	0.000439	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	6.4e-05	0.000434	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP3—malignant glioma	6.37e-05	0.000431	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—malignant glioma	6.36e-05	0.000431	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—malignant glioma	6.34e-05	0.000429	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	6.26e-05	0.000424	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—DTX1—malignant glioma	6.26e-05	0.000424	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—malignant glioma	6.2e-05	0.00042	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	6.17e-05	0.000418	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ASMT—malignant glioma	6.17e-05	0.000418	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	6.15e-05	0.000417	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	6.09e-05	0.000412	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	6.03e-05	0.000408	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP9—malignant glioma	6.02e-05	0.000408	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTEN—malignant glioma	5.98e-05	0.000405	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—malignant glioma	5.91e-05	0.0004	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BCAN—malignant glioma	5.8e-05	0.000393	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—malignant glioma	5.77e-05	0.000391	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	5.74e-05	0.000389	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	5.56e-05	0.000376	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	5.52e-05	0.000374	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	5.49e-05	0.000372	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—malignant glioma	5.4e-05	0.000366	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—malignant glioma	5.35e-05	0.000362	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—malignant glioma	5.21e-05	0.000353	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	5.19e-05	0.000352	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—COX8A—malignant glioma	5.14e-05	0.000348	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MYC—malignant glioma	4.97e-05	0.000337	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—malignant glioma	4.96e-05	0.000336	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HEY2—malignant glioma	4.91e-05	0.000333	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—malignant glioma	4.86e-05	0.000329	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IDH1—malignant glioma	4.8e-05	0.000325	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	4.69e-05	0.000318	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	4.68e-05	0.000317	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—IDH2—malignant glioma	4.67e-05	0.000317	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—malignant glioma	4.59e-05	0.000311	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HEY1—malignant glioma	4.55e-05	0.000308	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	4.44e-05	0.000301	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIST1H3B—malignant glioma	4.42e-05	0.000299	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	4.41e-05	0.000299	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2B6—malignant glioma	4.4e-05	0.000298	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	4.38e-05	0.000296	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ASMT—malignant glioma	4.37e-05	0.000296	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TFRC—malignant glioma	4.37e-05	0.000296	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	4.36e-05	0.000295	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	4.31e-05	0.000292	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	4.31e-05	0.000292	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—malignant glioma	4.22e-05	0.000286	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	4.22e-05	0.000286	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	4.22e-05	0.000286	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BCAN—malignant glioma	4.11e-05	0.000278	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—malignant glioma	4.08e-05	0.000277	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JAG2—malignant glioma	4.04e-05	0.000273	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—IDH1—malignant glioma	4.02e-05	0.000272	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	4.02e-05	0.000272	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—malignant glioma	4.01e-05	0.000272	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	3.99e-05	0.00027	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	3.92e-05	0.000265	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SPHK1—malignant glioma	3.89e-05	0.000263	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC6A3—malignant glioma	3.82e-05	0.000259	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2C18—malignant glioma	3.81e-05	0.000258	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	3.68e-05	0.000249	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	3.66e-05	0.000248	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	3.59e-05	0.000243	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	3.54e-05	0.00024	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—malignant glioma	3.45e-05	0.000234	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—H3F3A—malignant glioma	3.41e-05	0.000231	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	3.32e-05	0.000225	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—IDH2—malignant glioma	3.31e-05	0.000224	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	3.27e-05	0.000222	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JAG1—malignant glioma	3.22e-05	0.000218	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	3.16e-05	0.000214	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FBXW7—malignant glioma	3.15e-05	0.000214	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2B6—malignant glioma	3.12e-05	0.000211	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTT1—malignant glioma	3.08e-05	0.000209	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	3.06e-05	0.000207	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	2.99e-05	0.000203	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	2.99e-05	0.000203	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTGS1—malignant glioma	2.89e-05	0.000196	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	2.88e-05	0.000195	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—IDH1—malignant glioma	2.85e-05	0.000193	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	2.85e-05	0.000193	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	2.83e-05	0.000191	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SPHK1—malignant glioma	2.76e-05	0.000187	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2C18—malignant glioma	2.7e-05	0.000183	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BCHE—malignant glioma	2.68e-05	0.000182	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC5A5—malignant glioma	2.65e-05	0.00018	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	2.6e-05	0.000176	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	2.51e-05	0.00017	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	2.51e-05	0.00017	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN2B—malignant glioma	2.47e-05	0.000167	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HES1—malignant glioma	2.36e-05	0.00016	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NCOR1—malignant glioma	2.34e-05	0.000159	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFRA—malignant glioma	2.24e-05	0.000152	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—malignant glioma	2.18e-05	0.000148	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	2.17e-05	0.000147	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—malignant glioma	2.14e-05	0.000145	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	2.12e-05	0.000144	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAT—malignant glioma	2.08e-05	0.000141	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—malignant glioma	2.07e-05	0.00014	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HLA-A—malignant glioma	2.07e-05	0.00014	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS1—malignant glioma	2.05e-05	0.000139	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFB—malignant glioma	2.02e-05	0.000137	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR1—malignant glioma	2.01e-05	0.000136	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIF1A—malignant glioma	1.98e-05	0.000134	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NCOR1—malignant glioma	1.96e-05	0.000133	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CAV1—malignant glioma	1.91e-05	0.000129	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BCHE—malignant glioma	1.9e-05	0.000129	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC5A5—malignant glioma	1.88e-05	0.000127	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BAD—malignant glioma	1.8e-05	0.000122	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOTCH1—malignant glioma	1.78e-05	0.000121	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD80—malignant glioma	1.74e-05	0.000118	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—malignant glioma	1.74e-05	0.000118	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	1.73e-05	0.000117	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGF—malignant glioma	1.72e-05	0.000117	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTPN11—malignant glioma	1.71e-05	0.000116	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—malignant glioma	1.64e-05	0.000111	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CAV1—malignant glioma	1.6e-05	0.000108	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT2—malignant glioma	1.59e-05	0.000108	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CD—malignant glioma	1.53e-05	0.000104	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.53e-05	0.000104	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—malignant glioma	1.51e-05	0.000103	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAT—malignant glioma	1.47e-05	9.98e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF2—malignant glioma	1.47e-05	9.92e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—malignant glioma	1.46e-05	9.87e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—malignant glioma	1.41e-05	9.53e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NCOR1—malignant glioma	1.39e-05	9.43e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MDM2—malignant glioma	1.37e-05	9.29e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RAF1—malignant glioma	1.37e-05	9.25e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—malignant glioma	1.35e-05	9.15e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CB—malignant glioma	1.33e-05	9.03e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CD—malignant glioma	1.28e-05	8.68e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—malignant glioma	1.15e-05	7.81e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CAV1—malignant glioma	1.13e-05	7.68e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CB—malignant glioma	1.12e-05	7.57e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—malignant glioma	1.03e-05	7e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—malignant glioma	1.03e-05	6.98e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—malignant glioma	9.97e-06	6.76e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—malignant glioma	9.65e-06	6.54e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—malignant glioma	9.58e-06	6.49e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—malignant glioma	9.37e-06	6.35e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CD—malignant glioma	9.08e-06	6.15e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—malignant glioma	8.85e-06	5.99e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—malignant glioma	8.13e-06	5.51e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CB—malignant glioma	7.92e-06	5.36e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—malignant glioma	7.85e-06	5.31e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—malignant glioma	6.84e-06	4.63e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—malignant glioma	6.81e-06	4.61e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—malignant glioma	6.64e-06	4.5e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—malignant glioma	5.56e-06	3.77e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—malignant glioma	4.83e-06	3.27e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—malignant glioma	3.94e-06	2.67e-05	CbGpPWpGaD
